Candidate Drug designated within the Medivir Tibotec Collaboration
The hepatitis C Virus (HCV) collaboration of Medivir AB with Tibotec Pharmaceuticals Ltd has recently designated a Candidate Drug (CD). The aim of the research collaboration is to identify and develop orally active inhibitors of the HCV protease NS3/4A. The collaboration was initiated in November 2004 and attaining a CD designation represents an important step on the way towards clinical development.
Separately, the first milestone for preclinical development has been reached in the program, triggering a milestone payment to Medivir of EUR5m.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.